Mixed‐effects models for slope‐based endpoints in clinical trials of chronic kidney disease
In March of 2018, the National Kidney Foundation, in collaboration with the US Food and Drug Administration and the European Medicines Agency, sponsored a workshop in which surrogate endpoints other than currently established event‐time endpoints for clinical trials in chronic kidney disease (CKD) w...
Автори: | Vonesh, E, Tighiouart, H, Ying, J, Heerspink, HL, Lewis, J, Staplin, N, Inker, L, Greene, T |
---|---|
Формат: | Journal article |
Мова: | English |
Опубліковано: |
Wiley
2019
|
Схожі ресурси
Схожі ресурси
-
Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trials
за авторством: Willem Collier, та інші
Опубліковано: (2024-02-01) -
A meta-analysis of GFR slope as a surrogate endpoint for kidney failure
за авторством: Inker, LA, та інші
Опубліковано: (2023) -
Acute treatment effects on GFR in randomized clinical trials of kidney disease progression
за авторством: Neuen, B, та інші
Опубліковано: (2021) -
Allograft function as endpoint for clinical trials in kidney transplantation
за авторством: Hilbrands, L, та інші
Опубліковано: (2022) -
Patient-reported outcomes as endpoints in clinical trials of kidney transplantation interventions
за авторством: Tong, A, та інші
Опубліковано: (2022)